Clinical Trials Browser

Phase 1/2 × navitoclax × 90 days × Clear all

NCT01989585 2026-03-19

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Phase 1/2 Active not recruiting

Melanoma